By Judy George, Deputy Managing Editor, MedPage Today
October 21, 2026
In a groundbreaking development that bridges the gap between psychiatric research and neurology, a new study suggests that psilocybin therapy may do more than alleviate mood disorders—it may actively alter the underlying biological processes associated with Parkinson’s disease. For the first time, researchers have documented a reduction in markers of systemic inflammation and mitochondrial stress following psilocybin administration in patients suffering from the neurodegenerative condition.
The findings, published in JAMA Psychiatry, represent a significant shift in the scientific understanding of psychedelic therapeutics. While psilocybin has long been studied for its potential to treat depression, anxiety, and addiction, this is the first report of biological changes in a neurodegenerative disorder population, opening a new frontier in clinical neurology.
Main Facts: A New Mechanism for Neurodegenerative Care
The small, nonrandomized open-label trial conducted by investigators at the University of California San Francisco (UCSF) involved 12 participants, aged 40 to 75, diagnosed with mild-to-moderate Parkinson’s disease. Participants were administered two doses of oral synthetic psilocybin—10 mg and 25 mg—spaced approximately two weeks apart.
The study’s primary objective was to track changes in a "proinflammatory index," a composite score derived from key biomarkers including interleukin (IL)-6, IL-8, tumor necrosis factor alpha, interferon gamma, and high-sensitivity C-reactive protein. Additionally, researchers monitored GDF-15 and FGF-21 as indicators of mitochondrial stress.
The data revealed a statistically significant reduction in the inflammatory index across all follow-up intervals when compared to baseline. Specifically, the standard mean difference (SMD) was -0.72 (adjusted P=0.003) one day after the 10-mg dose. Similar reductions persisted after the 25-mg dose, with an SMD of -0.60 (adjusted P=0.02) one day post-administration and -0.62 (adjusted P=0.047) at the 30-day mark.
Chronology of the Investigation
The study design followed a rigorous, multi-point collection process to map the biological footprint of the psychedelic intervention.
- Baseline Collection: Before any psilocybin was administered, plasma samples were collected from participants to establish a personal biological benchmark.
- Phase 1 (10-mg dose): Plasma was sampled one day after the initial administration. Researchers noted a significant drop in IL-6, a key proinflammatory cytokine, and a concomitant rise in the anti-inflammatory cytokine IL-10, though these specific components did not sustain significant changes at later time points.
- Phase 2 (25-mg dose): Following the second, higher-dose administration, plasma was sampled one day later. During this phase, GDF-15 levels—a marker associated with mitochondrial stress—showed a significant decrease relative to baseline.
- Final Follow-up: At 30 days post-treatment, the reduction in the overall inflammatory index remained significant, suggesting a potentially durable biological effect rather than a transient reaction to the drug.
Supporting Data and Biological Indicators
The physiological impact of psilocybin in this cohort was not limited to systemic inflammation. Mitochondrial health, which is frequently compromised in Parkinson’s disease, also appeared to respond to the treatment.
Growth differentiation factor 15 (GDF-15) levels were notably lower 24 hours after both the 10-mg and 25-mg doses. While fibroblast growth factor 21 (FGF-21) levels were also measured, the researchers noted that while these levels trended higher one day after administration, the shift did not reach statistical significance.
The researchers emphasize that these markers were chosen specifically because systemic inflammation is known to exacerbate neurodegeneration. By reducing the overall inflammatory load, the therapy may theoretically slow the progression of symptoms or improve the quality of life for patients. This supports findings from a parent trial by the same UCSF team, which previously linked psilocybin therapy to measurable improvements in motor symptoms, depression, and anxiety among the same cohort.
Official Responses and Expert Perspectives
The academic community has received these findings with cautious optimism. Albert Garcia-Romeu, PhD, of the Johns Hopkins University School of Medicine, who was not involved in the UCSF study, described the results as a pivotal step forward.
"Much of the work looking at psilocybin or LSD has focused squarely on mental health conditions like depression, anxiety, or addiction," Garcia-Romeu told MedPage Today. "However, this study is in patients with a neurological condition—Parkinson’s disease—and shows evidence that psilocybin may have impacted biological markers of inflammation and mitochondrial stress."
He further noted the broader context of this research, referencing recent studies in mice where psilocybin appeared to block nerve damage related to chemotherapy. "These new data suggest biological effects of psychedelics could be driving potential benefits in patients and pave the way for more work to better understand how psilocybin might be a useful therapeutic both in psychiatric and non-psychiatric conditions," Garcia-Romeu added.
Lead researcher Ellen Bradley, MD, of UCSF, expressed that the study serves as a catalyst for a new line of inquiry. "To our knowledge, this is the first report of changes in these types of markers after psychedelic treatment in people with a neurodegenerative disease," Bradley stated. "That gives us and other researchers super-interesting biological questions to pursue: What could be producing these changes, are they consistent in larger groups of people, and do they have anything to do with clinical benefits people with Parkinson’s might experience with psilocybin?"
Implications for Future Research
The limitations of the study are clear: the small sample size of 12 participants and the open-label, nonrandomized nature of the trial mean that these results should be interpreted with caution. However, the potential implications are profound.
Aoife O’Donovan, PhD, a co-author on the study, emphasized that the team is already pivoting toward more robust methodologies. "The results are highly promising and suggest that more research in this area is warranted," O’Donovan told MedPage Today. "We are already following this study up with more in-depth analyses of the effects of psilocybin therapy on inflammation and mitochondrial stress in a randomized controlled trial in patients with Parkinson’s disease."
The shift toward treating neurodegeneration via immunological and metabolic pathways marks a departure from traditional dopaminergic therapies for Parkinson’s. If systemic inflammation is indeed a modifiable target through psychedelic-assisted therapy, it could provide a secondary line of defense for patients who have not found adequate relief from current standard-of-care medications.
As the field matures, other neurodegenerative conditions are also being put under the microscope. Garcia-Romeu’s laboratory is currently nearing the completion of a trial involving 20 individuals with mild cognitive impairment or early-stage Alzheimer’s disease. With 18 patients already treated, the findings from that study—expected next year—will likely provide further insight into whether the anti-inflammatory effects observed in the Parkinson’s cohort are a broader feature of psilocybin’s biological mechanism.
For now, the UCSF study provides a compelling biological hypothesis: that the therapeutic potential of psilocybin may extend far beyond the psychological, potentially influencing the very cellular integrity of the aging and diseased brain. As researchers move into randomized controlled trials, the medical community will be watching closely to see if these promising biomarkers translate into long-term clinical stabilization for Parkinson’s patients.
